Last reviewed · How we verify

Abiraterone acetate escalated dose

Assistance Publique - Hôpitaux de Paris · Phase 2 active Small molecule

Abiraterone acetate escalated dose is a CYP17A1 inhibitor Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development for Metastatic castration-resistant prostate cancer, Castration-sensitive prostate cancer (in combination with androgen deprivation therapy).

Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis, reducing testosterone production to treat androgen-dependent cancers.

Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis, reducing testosterone production to treat androgen-dependent cancers. Used for Metastatic castration-resistant prostate cancer, Castration-sensitive prostate cancer (in combination with androgen deprivation therapy).

At a glance

Generic nameAbiraterone acetate escalated dose
SponsorAssistance Publique - Hôpitaux de Paris
Drug classCYP17A1 inhibitor
TargetCYP17A1 (17α-hydroxylase/17,20-lyase)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Abiraterone acetate inhibits the enzyme 17α-hydroxylase/17,20-lyase (CYP17A1), which is critical for androgen biosynthesis in the adrenal glands and tumor cells. By blocking this enzyme, it reduces circulating and intratumoral testosterone levels, thereby suppressing androgen receptor signaling in hormone-sensitive cancers. The escalated dose regimen aims to achieve higher drug exposure for potentially improved efficacy in advanced disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Abiraterone acetate escalated dose

What is Abiraterone acetate escalated dose?

Abiraterone acetate escalated dose is a CYP17A1 inhibitor drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Metastatic castration-resistant prostate cancer, Castration-sensitive prostate cancer (in combination with androgen deprivation therapy).

How does Abiraterone acetate escalated dose work?

Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis, reducing testosterone production to treat androgen-dependent cancers.

What is Abiraterone acetate escalated dose used for?

Abiraterone acetate escalated dose is indicated for Metastatic castration-resistant prostate cancer, Castration-sensitive prostate cancer (in combination with androgen deprivation therapy).

Who makes Abiraterone acetate escalated dose?

Abiraterone acetate escalated dose is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What drug class is Abiraterone acetate escalated dose in?

Abiraterone acetate escalated dose belongs to the CYP17A1 inhibitor class. See all CYP17A1 inhibitor drugs at /class/cyp17a1-inhibitor.

What development phase is Abiraterone acetate escalated dose in?

Abiraterone acetate escalated dose is in Phase 2.

What are the side effects of Abiraterone acetate escalated dose?

Common side effects of Abiraterone acetate escalated dose include Hypokalemia, Hypertension, Fluid retention/edema, Fatigue, Diarrhea, Nausea.

What does Abiraterone acetate escalated dose target?

Abiraterone acetate escalated dose targets CYP17A1 (17α-hydroxylase/17,20-lyase) and is a CYP17A1 inhibitor.

Related